Sorry, your right, 20-30 after tax. It was late. Having said that tax is difficult to estimate because of the foreign nature in this case and franking credits for domestic tax. Looking at my numbers, it is easier to use 6-8x revenue for straight pharma's. So, initial opportunity, US$540-720 million for US for TKI, initial off-label.(AUS$620-AUS$830; At long term ave forex rate of 75 cents: AUS$720-AUS$960, I knew I had a bil somewhere in my numbers)
I can't think of one either, but I focus very much on the OZ market.
The margin is so high because the patients are already known to doctors and already known to need a new treatment. Drs are specialists and very easy to find/contact (the principal investigators of the study could probably name 90% of them), probably major medical centres only given the rarity of the disease. Also, of course, the drug doesn't cost much to make, but will be very expensive. It is a very unique opportunity.
You are on the board of Avantogen.
Cheers,
BW
CXS Price at posting:
70.0¢ Sentiment: Buy Disclosure: Held
